From sorting to sequencing in the molecular era: the evolution of the cancer stem cell model in medulloblastoma.

The cancer stem cell (CSC) model posits that tumors contain subpopulations that display defining features of normal stem cells including self-renewal capacity and differentiation. Tumor cells exhibiting these features are now considered to be responsible for tumor propagation and drug resistance in a wide variety of cancers. Therefore, identification of robust CSC markers and characterization of CSC-specific molecular signatures may lead to identification of novel therapeutics that selectively abolish this clinically relevant cell population while preserving normal tissue. Brain tumor researchers have been at the forefront of the CSC field. From initial in vitro cell sorting experiments to the sophisticated bioinformatics technologies that now exquisitely resolve primary brain tumors at a single cell level, recent glioma and medulloblastoma (MB) studies have integrated developmental state with genomic and transcriptome data to identify the spectrum of cell types that may drive tumor progression. This review will examine the last two decades of CSC studies in the field. Seminal discoveries, emerging controversies and outstanding questions will be covered with a particular focus on MB, the most common malignant primary brain tumor in children.
This article is protected by copyright. All rights reserved.